Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bio-Rad Expands Portfolio of PrimePCR™ Assays for Droplet Digital™ PCR

Published: Wednesday, May 21, 2014
Last Updated: Wednesday, May 21, 2014
Bookmark and Share
Company expands its collection of validated assays for mutation detection and copy number variation.

Bio-Rad Laboratories, Inc. announces an expansion of its line of PrimePCR probe assays for Droplet Digital PCR that adds another 56 assays for mutation detection and 109 assays for copy number variation (CNV) analysis to Bio-Rad’s catalog of existing assays for use on its QX100™ and QX200™ Droplet Digital PCR systems.

biorad_primePCR.gifThe new Droplet Digital PCR (ddPCR™) assays are the only available assays that are predesigned and fully wet-lab validated for digital PCR, which frees researchers from time-consuming and labor-intensive assay design and experiment optimization.

Many conventional methods, such as qPCR and next-generation sequencing, offer poor selectivity, fail to detect events with frequencies of less than one in 100 wild-type sequences, and lack the resolution needed to accurately analyze CNV. However, Bio-Rad’s ddPCR technology provides an absolute measure of target DNA molecules and, together with PrimePCR mutation detection assays, can enable detection of one mutant molecule in a background of 2,000 wild-type molecules in a single well without the need for a standard curve. Measuring these extremely low levels of mutation abundance could lead to the development of new diagnostics that are less invasive and dramatically more sensitive. In addition, the high precision and absolute quantification made possible by PrimePCR ddPCR assays enable the quantitative discrimination
required to resolve small fold changes in gene copy numbers for CNV analysis.

Professor Per Guldberg, a group leader at the Danish Cancer Society, has been using PrimePCR ddPCR assays to detect mutations in neoplastic cells from body fluids. The assays are helping his lab uncover oncogenic biomarkers for bladder cancer, malignant melanoma, and other types of cancers.

“We have found the PrimePCR digital PCR assays to be very robust and specific with a high signal-to-noise ratio,” said Guldberg. “They have also helped us by entirely eliminating the need for cumbersome assay design and optimization.”

The mutation detection assays include those for deletions in the anaplastic lymphoma kinase (ALK) gene, which are believed to be associated with acquired resistance to ALK tyrosine kinase inhibitor (TKI) cancer therapy. The assays also target mutations associated with other cancers such as pancreatic cancer, melanoma, and lymphomas. Many of the CNV assay targets are associated with cancers (leukemia, melanoma, and uveal melanoma) and neurological diseases.

PrimePCR digital PCR assays are available in multiple reaction sizes and are compatible with both the QX100 and QX200 ddPCR systems using the ddPCR supermix for probes (no dUTP).


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Droplet Digital PCR Enables Measurement of Potential Cancer Survival Biomarker
Study paves the way for further research into the role of TIL quantification in immunotherapy and as a cancer survival predictor.
Tuesday, December 10, 2013
Researchers Develop Rapid, Cost-Effective Early Detection Method for Organ Transplant Injury
Chronix Biomedical and transplant expert Prof. Oellerich use Droplet Digital™ PCR to quantify early rejection biomarker.
Thursday, August 29, 2013
New Biomarker Could Reveal Alzheimer's Disease Years Before Onset
A new study has reported the identification of what may be the earliest known biomarker associated with the risk of developing Alzheimer's disease (AD).
Wednesday, August 14, 2013
Bio-Rad Receives Award for QX100 Droplet Digital PCR System
Company receives Frost & Sullivan 2012 North American Laboratory Researchers’ Choice: Future market leader of digital PCR technology award.
Thursday, March 14, 2013
Bio-Rad and Myriad RBM Partner to Develop Immunoassay Kits
Partnership to commercialize multiplex biomarker kits for life science research.
Wednesday, August 01, 2012
Case Study Demonstrates Importance of MIQE for qPCR Data Analysis
Published by Bio-Rad Laboratories, Inc. this case study demonstrates how real-time PCR can lead to erroneous conclusions if the key steps set out in the MIQE guidelines are not followed.
Friday, February 17, 2012
Bio-Rad Acquires QuantaLife and Digital PCR Technology
Bio-Rad purchases QuantaLife for $162 million in cash plus potential future milestone payments.
Friday, October 07, 2011
Bio-Rad Describes Detailed Neuroblastoma Study Using qPCR Analysis
The study uses examples from neuroblastoma research conducted at Bio-Rad and by researchers at Ghent University, Belgium.
Monday, August 04, 2008
Bio-Rad Introduces new Pro-Human Diabetes Assay Panel
The Company has launched new Bio-Plex Pro™ Human Diabetes Assay Panels for its Bio-Plex® suspension array system.
Tuesday, June 24, 2008
Bio-Rad Study Describes Evaluation of Cancer Biomarkers
Bio-Rad researchers evaluated the Bio-Plex® suspension array system’s ability to detect the levels of nine biomarkers.
Wednesday, June 11, 2008
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Study Identifies the Off Switch for Biofilm Formation
New discovery could help prevent the formation of infectious bacterial films on hospital equipment.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Combo Tool
Joining molecular components expands ability to manipulate genes in specific cell types.
Team Identifies Structure of Tumor-Suppressing Protein
An international group of researchers led by Carnegie Mellon University physicists Mathias Lösche and Frank Heinrich have established the structure of an important tumor suppressing protein, PTEN.
Genes Associated With Improved Survival for Pancreatic Cancer Patients
Use of non-invasive liquid biopsies could predict in which patients the cancer could recur following surgery.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!